Xencor, Inc. – Product Pipeline Review – Q1 2011 by GlobalMarketsDirect

VIEWS: 2 PAGES: 47

Xencor, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Xencor, Inc. - Product Pipeline Review - Q1 2011” provides data on the Xencor, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xencor, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xencor, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Xencor, Inc. - Brief Xencor, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xencor, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xencor, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xencor, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Xencor, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xencor, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xencor, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

More Info
									        Xencor, Inc. – Product Pipeline Review – Q1 2011
                                                                                          Reference Code: GMDHC1265CDB

                                                                                                Publication Date: JUN 2011




Xencor, Inc. – Product Pipeline Review – Q1 2011                                            GMDHC1265CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Xencor, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Xencor, Inc. Snapshot                                                                                                 5
    Xencor, Inc. Overview                                                                                             5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Xencor, Inc. – Research and Development Overview                                                                      6
    Key Therapeutic Areas                                                                                             6
Xencor, Inc. – Pipeline Review                                                                                        9
    Pipeline Products by Stage of Development                                                                         9
    Pipeline Products – Monotherapy                                                                                  10
Xencor, Inc. – Pipeline Products Glance                                                                              11
    Xencor, Inc. Clinical Stage Pipeline Products                                                                    11
         Phase I Products/Combination Treatment Modalities                                                           11
    Xencor, Inc.–Early Stage Pipeline Products                                                                       12
         Pre-Clinical Products/Combination Treatment Modalities                                                      12
         Discovery Products/Combination Treatment Modalities                                                         13
Xencor, Inc. – Drug Profiles                                                                                         14
    XmAb 2513                                                                                                        14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
    XmAb 5485                                                                                                        15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    XmAb 5871                                                                                                        16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    XmAb-5483                                                                                                        17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    Xmab5592                                                                                                         18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    XmAb7195                                                                                                         19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    Xpro1595                                                                                                         20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20




Xencor, Inc. – Product Pipeline Review – Q1 2011                                          GMDHC1265CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Xencor, Inc. – Product Pipeline Review



         R&D Progress                                                                                                    20
    CD5                                                                                                                  21
         Product Description                                                                                             21
         Mechanism of Action                                                                                             21
         R&D Progress                                                                                                    21
    EGFR                                                                                                                 22
         Product Description                                                                                             22
         Mechanism of Action                                                                                             22
         R&D Progress                                                                                                    22
Xencor, Inc. – Pipeline Analysis                                                                                         23
    Xencor, Inc. – Pipeline Products by Therapeutic Class                                                                23
    Xencor, Inc. - Pipeline Products By Target                                                                           24
    Xencor, Inc. – Pipeline Products by Route of Administration                                                          25
    Xencor, Inc. – Pipeline Products by Molecule Type                                                                    26
Xencor, Inc. – Recent Pipeline Updates                                                                                   27
Xencor, Inc. – Locations And Subsidiaries                                                                                28
    Head Office                                                                                                          28
Financial Deals Landscape                                                                                                29
    Xencor, Inc., Deals Volume Summary, 2004 to YTD 2011                                                                 29
    Xencor, Inc., Deals Summary By Region, 2004 to YTD 2011                                                              30
    Xencor, Inc., Deals Summary, 2004 to YTD 2011                                                                        31
    Xencor, Inc. Detailed Deal Summary                                                                                   32
         Venture Financing                                                                                               32
         Xencor Completes $45 Million Venture Financing Round                                                            32
         Human Genome Sciences Enters Into Collaboration With Xencor                                                     34
         Licensing Agreements                                                                                            35
         Xencor Enters Into Licensing Agreement With Centocor For XmAb And Xtend Technology                              35
         Xencor Enters Into Licensing Agreement With Merck                                                               36
         Xencor Enters Into Licensing Agreement With Pfizer                                                              37
         Xencor Enters Into Licensing Agreement With CSL                                                                 38
         Boehringer Ingelheim Enters Into Licensing Agreement With Xencor                                                39
         Xencor Enters Into Licensing Agreement With Centocor For ImmunoFilter Technology                                40
         Xencor Enters Into Licensing Agreement With Eli Lilly and Company                                               41
         MedImmune Enters Into An Agreement With Xencor                                                                  42
         Xencor Enters Into Licensing Agreement With Eli Lilly                                                           43
         Chugai Pharmaceutical Signs Agreement With Xencor                                                               44
         Xencor Enetrs Into Licensing Agreement With Genentech                                                           45
Appendix                                                                                                          
								
To top